218 related articles for article (PubMed ID: 18281707)
1. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Takiuchi H; Goto M; Imamura H; Furukawa H; Imano M; Imamoto H; Kimura Y; Ishida H; Fujitani K; Narahara H; Shimokawa T
Jpn J Clin Oncol; 2008 Mar; 38(3):176-81. PubMed ID: 18281707
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
[TBL] [Abstract][Full Text] [Related]
4. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Ina K; Sugihara M; Haruta J; Shinoda M; Kumada T; Goto H
Oncology; 2011; 80(1-2):76-83. PubMed ID: 21659786
[TBL] [Abstract][Full Text] [Related]
5. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
6. Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.
Yoshino S; Furuya T; Shimizu R; Ozasa H; Nishimura T; Fukuda S; Kawaoka T; Hazama S; Oka M
Anticancer Res; 2013 Jun; 33(6):2629-33. PubMed ID: 23749919
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer.
Takeyoshi I; Makita F; Tanahashi Y; Iwazaki S; Ogawa T; Tomizawa N; Nakamura S; Ishikawa H; Ohya T; Kakinuma S; Nakagami K; Sato Y; Koyano T; Roppongi T; Izumi M; Kobayashi J; Kawate S; Sunose Y; Kobayashi M; Yamada T; Sakamoto I
Anticancer Res; 2011 Jan; 31(1):287-91. PubMed ID: 21273612
[TBL] [Abstract][Full Text] [Related]
8. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
9. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
11. [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
Mizutani S; Oyama T; Hatanaka N; Uchikoshi F; Yoshidome K; Tori M; Ueshima S; Okuma K; Hiraoka K; Yamagami Y; Takahashi H; Sueyoshi K; Taira M; Nakahara M; Nakao K
Gan To Kagaku Ryoho; 2006 Mar; 33(3):327-31. PubMed ID: 16531712
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
[TBL] [Abstract][Full Text] [Related]
14. [A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].
Kuwakado S; Takiuchi H; Goto M; Kawabe S; Ohta S; Kii T; Tanaka T; Nishitani H; Katsu K
Gan To Kagaku Ryoho; 2006 Apr; 33(4):513-5. PubMed ID: 16612164
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
Yoshida T; Yoshikawa T; Tsuburaya A; Kobayashi O; Hasegawa S; Osaragi T; Sairenji M
Anticancer Res; 2006; 26(2B):1595-8. PubMed ID: 16619577
[TBL] [Abstract][Full Text] [Related]
16. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
[TBL] [Abstract][Full Text] [Related]
19. Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1.
Arai W; Hosoya Y; Hyodo M; Haruta H; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Sakuma K; Yasuda Y; Nagai H
Int J Clin Oncol; 2007 Apr; 12(2):146-9. PubMed ID: 17443283
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
